Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)

Alan Maisel, Yang Xue, Dirk J. Van Veldhuisen, Adriaan A. Voors, Tiny Jaarsma, Peter Pang, Javed Butler, Bertram Pitt, Paul Clopton, Rudolf A. De Boer

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.

Original languageEnglish (US)
Pages (from-to)737-742
Number of pages6
JournalThe American Journal of Cardiology
Volume114
Issue number5
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Spironolactone
Heart Failure
Galectin 3
Brain Natriuretic Peptide
Creatinine
Biomarkers
Mortality
Patient Discharge
Counseling
Hospitalization
Outcome Assessment (Health Care)
Physicians

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study). / Maisel, Alan; Xue, Yang; Van Veldhuisen, Dirk J.; Voors, Adriaan A.; Jaarsma, Tiny; Pang, Peter; Butler, Javed; Pitt, Bertram; Clopton, Paul; De Boer, Rudolf A.

In: The American Journal of Cardiology, Vol. 114, No. 5, 01.09.2014, p. 737-742.

Research output: Contribution to journalArticle

Maisel, A, Xue, Y, Van Veldhuisen, DJ, Voors, AA, Jaarsma, T, Pang, P, Butler, J, Pitt, B, Clopton, P & De Boer, RA 2014, 'Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)', The American Journal of Cardiology, vol. 114, no. 5, pp. 737-742. https://doi.org/10.1016/j.amjcard.2014.05.062
Maisel, Alan ; Xue, Yang ; Van Veldhuisen, Dirk J. ; Voors, Adriaan A. ; Jaarsma, Tiny ; Pang, Peter ; Butler, Javed ; Pitt, Bertram ; Clopton, Paul ; De Boer, Rudolf A. / Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study). In: The American Journal of Cardiology. 2014 ; Vol. 114, No. 5. pp. 737-742.
@article{b761be65791c42aaaee601ed9613e251,
title = "Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)",
abstract = "The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6{\%}) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.",
author = "Alan Maisel and Yang Xue and {Van Veldhuisen}, {Dirk J.} and Voors, {Adriaan A.} and Tiny Jaarsma and Peter Pang and Javed Butler and Bertram Pitt and Paul Clopton and {De Boer}, {Rudolf A.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.amjcard.2014.05.062",
language = "English (US)",
volume = "114",
pages = "737--742",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)

AU - Maisel, Alan

AU - Xue, Yang

AU - Van Veldhuisen, Dirk J.

AU - Voors, Adriaan A.

AU - Jaarsma, Tiny

AU - Pang, Peter

AU - Butler, Javed

AU - Pitt, Bertram

AU - Clopton, Paul

AU - De Boer, Rudolf A.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.

AB - The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=84908372824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908372824&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2014.05.062

DO - 10.1016/j.amjcard.2014.05.062

M3 - Article

C2 - 25129066

AN - SCOPUS:84908372824

VL - 114

SP - 737

EP - 742

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -